Skip to main content
Top
Published in: Clinical and Translational Oncology 1/2013

01-01-2013 | Editorial

A 10-year step forward in hereditary cancer in Spain

Authors: B. Graña, J. Balmaña

Published in: Clinical and Translational Oncology | Issue 1/2013

Login to get access

Excerpt

Genetic counselling in cancer is a multistep medical process that includes cancer risk assessment, evaluation of patient’s needs and concerns, education, genetic testing in selected cases, medical management, and psychosocial support. Potential benefits, limitations and risks of gene tests are important considerations in the decision-making process. The most detrimental factor in the development of genetic counselling in hereditary cancer in Spain in the late 90’s was the lack of certified formation and training in this field. To solve this gap, a tremendous effort has been done from the Spanish Society of Medical Oncology (SEOM) by promoting training courses, publishing books, guidelines, and consensus documents, fostering multidisciplinary meetings to address controversial issues, and participating in research projects. In June 2000, the first Spanish working group in hereditary cancer was created. A key priority was making genetic counselling in cancer accessible to anyone in Spain, uniting for this purpose the expertise of different motivated health professionals, such as oncologists, geneticists, nurses, psychologists, and others. …
Literature
Metadata
Title
A 10-year step forward in hereditary cancer in Spain
Authors
B. Graña
J. Balmaña
Publication date
01-01-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 1/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-012-0973-1

Other articles of this Issue 1/2013

Clinical and Translational Oncology 1/2013 Go to the issue

Acknowledgements to Referees

Acknowledgements to Referees 2012

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine